Delivery Order SPE2DB20D3103-SPE2DB25FP8L6
- Not listed
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $18,748.72 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with performance completion by September 30, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger federal contracting vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,061.54 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded procurement. Performance will be completed by September 5, 2025, with the product supplied from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The contract is performed from the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award status. Performance will be completed by September 5, 2025, with all work performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of July 11, 2025. This firm fixed-price, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors on September 17, 2025, with completion scheduled for October 8, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award issued to support federal pharmaceutical supply needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors valued at $4,687.18, with completion targeted for September 29, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8L6Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance will be completed by September 3, 2025, with fulfillment conducted from the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a prime pharmaceutical distributor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to military and veteran healthcare systems. The parent IDC vehicle provides flexible, global pharmaceutical support across multiple therapeutic domains and enables the company to serve various federal healthcare customers, including the Defense Health Agency and U.S. Coast Guard. Tezspire is a specialty biologic medication used in the treatment of severe asthma, representing the type of specialized pharmaceutical commodity that falls within the company's extensive federal supply portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/12/25 |